[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2003249534A1 - 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors - Google Patents

6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors

Info

Publication number
AU2003249534A1
AU2003249534A1 AU2003249534A AU2003249534A AU2003249534A1 AU 2003249534 A1 AU2003249534 A1 AU 2003249534A1 AU 2003249534 A AU2003249534 A AU 2003249534A AU 2003249534 A AU2003249534 A AU 2003249534A AU 2003249534 A1 AU2003249534 A1 AU 2003249534A1
Authority
AU
Australia
Prior art keywords
matrix metalloproteinase
metalloproteinase inhibitors
fused heteroaryl
heteroaryl derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003249534A
Inventor
James Lester Hicks
William Howard Roark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2003249534A1 publication Critical patent/AU2003249534A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003249534A 2002-08-13 2003-08-04 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors Abandoned AU2003249534A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40324602P 2002-08-13 2002-08-13
US60/403,246 2002-08-13
PCT/IB2003/003494 WO2004014388A1 (en) 2002-08-13 2003-08-04 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
AU2003249534A1 true AU2003249534A1 (en) 2004-02-25

Family

ID=31715965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003249534A Abandoned AU2003249534A1 (en) 2002-08-13 2003-08-04 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors

Country Status (3)

Country Link
US (1) US20040043985A1 (en)
AU (1) AU2003249534A1 (en)
WO (1) WO2004014388A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539401A1 (en) * 2001-02-14 2002-10-28 Warner Lambert Co QUINAZOLINAS AS INHIBITORS OF MMP-13
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
DK1511734T3 (en) 2002-04-17 2010-08-02 Cytokinetics Inc Compounds, Preparations and Methods
DE60326248D1 (en) * 2002-07-17 2009-04-02 Cytokinetics Inc Compounds, compositions and methods for treating cellular proliferative disorders
PA8578101A1 (en) * 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
EP1554265A4 (en) * 2002-09-13 2008-05-07 Cytokinetics Inc Compounds, compositions and methods
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
WO2005042697A2 (en) * 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
AR055041A1 (en) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd TIADIAZOLS AND OXADIAZOLS AS INHIBITORS OF THE SYNTHESIS OF LEUCOTRIENOS. PHARMACEUTICAL COMPOSITIONS.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
WO2009015917A2 (en) 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
PL3071203T3 (en) 2013-11-18 2021-08-23 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
EP3286172B1 (en) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
US10736321B2 (en) * 2016-07-04 2020-08-11 Bayer Cropscience Aktiengesellschaft Benzosultams and analogues and their use as fungicides
JP7142633B2 (en) 2016-10-26 2022-09-27 コンステレーション・ファーマシューティカルズ・インコーポレイテッド LSD1 inhibitors and their medical uses
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626881B2 (en) * 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
EP0968190A1 (en) * 1997-03-18 2000-01-05 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
AU4249700A (en) * 1999-04-19 2000-11-02 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative
CA2403321C (en) * 2000-03-16 2009-07-14 Mitsubishi Pharma Corporation Amide compounds and use thereof
MXPA03005870A (en) * 2001-02-14 2005-02-14 Warner Lambert Co Benzo thiadiazine matrix metalloproteinase inhibitors.
WO2003032999A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
WO2004014388A8 (en) 2004-04-29
WO2004014388A1 (en) 2004-02-19
US20040043985A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
AU2003249534A1 (en) 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
AU2003249532A1 (en) 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250475A1 (en) 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
AU2003249531A1 (en) Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003255492A1 (en) Heterocyclic derivatives
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
AU2003216660A1 (en) N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
AU2003250482A1 (en) Phthalimide derivatives as matrix metalloproteinase inhibitors
ZA200408423B (en) Novel tetrahydropyridine derivatives as renin inhibitors.
AU2003219410A1 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
AU2003253150A1 (en) Chromone derivatives as matrix metalloproteinase inhibitors
AU2003250469A1 (en) Isoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253176A1 (en) Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003253186A1 (en) Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003216677A1 (en) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
AU2003249535A1 (en) 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003253149A1 (en) 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003269949A1 (en) Substituted 1,4-pyrazine derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase